ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy

BACKGROUND: Most studies utilizing circulating tumor DNA (ctDNA) to monitor disease interrogated only one or a few genes and failed to develop workable criteria to inform clinical practice. We evaluated the feasibility of detecting resistance to anti-HER2 therapy by serial gene-panel ctDNA sequencin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Fei, Zhu, Wenjie, Guan, Yanfang, Yang, Ling, Xia, Xuefeng, Chen, Shanshan, Li, Qiao, Guan, Xiuwen, Yi, Zongbi, Qian, Haili, Yi, Xin, Xu, Binghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323211/
https://www.ncbi.nlm.nih.gov/pubmed/27602761
http://dx.doi.org/10.18632/oncotarget.11791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323211/
https://www.ncbi.nlm.nih.gov/pubmed/27602761
http://dx.doi.org/10.18632/oncotarget.11791

Ejemplares similares